国际标准期刊号: 2161-0460

阿尔茨海默病和帕金森病杂志

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 期刊目录
  • 中国知网(CNKI)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

The Emergency of Nutraceutical Compounds in the Preventive Medicine Scenario. Potential for Treatment of Alzheimer's Disease and Other Chronic Disorders

Víctor Andrade, Leonardo Guzmán-Martínez, Nicole Cortés, Andrea González, Gonzalo Farías and Ricardo B Maccioni

Evidence-based Nutraceutical Compounds (EBNC), containing bioactive principles of demonstrated efficacy and health security are opening solutions for a modern preventive medicine, and as potential solutions for many chronic diseases of the human beings. EBNC contain bioactive components of the human diet that can be used for the prevention or treatment of a disease. They are obtained through rigorous processes of extraction from natural resources and Good Manufacturing Practices (GMP) regulations, and exhibit sound preclinical studies published in high impact medical journals, and double-blind placebo-controlled clinical trials. Are these compounds significantly more effective than alternative medicines? EBNC rely on some of the major advances in molecular genetics, epitranscriptomics, molecular biology and modern pharmacology. They are certainly opening a solid pathway in benefit of human health and the welfare of mankind.